Johannes M. Waldschmidt

Universitätsklinikum Würzburg — Germany

Medicine · Health Sciences

13h-index674citations199works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(127), Protein Degradation and Inhibitors(59), CAR-T cell therapy research(51), Melanoma and MAPK Pathways(29), Peptidase Inhibition and Analysis(19)

Publications199 total

Early Mortality with Bispecific Antibody Therapy in RRMM: An IMWG Immunotherapy Database Real-World Analysis
Blood Advances·2026Open Access
Clinical scores to predict toxicities and outcomes in patients with multiple myeloma undergoing bispecific T-cell engager therapy
Blood Cancer Discovery·2026
Real-world efficacy and tolerability of ixazomib-based combination therapies in advanced multiple myeloma and other plasma cell neoplasms
Therapeutic Advances in Hematology·2026Open Access
Significant burden of low-grade infections in patients treated with T-cell-engaging therapies for Multiple Myeloma
Blood Advances·2026Open Access
Patient Preferences for Treatment‑Free Intervals in Multiple Myeloma: Mixed‑Methods Insights on Monitoring Trade‑offs and Supportive Care Improvements
2026Open Access
Promoter hypermethylation as a reversible mechanism of resistance to GPRC5D-directed therapy in multiple myeloma
Haematologica·2026Open Access
Talquetamab‐Related Dysgeusia in Multiple Myeloma Compared to <scp>BCMA</scp> ‐Targeted Bispecifics and High‐Dose Melphalan
Cancer Medicine·2025· 1 citedOpen Access
Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR‐T therapy
HemaSphere·2025Open Access
Optimizing the use of melflufen (melphalan flufenamide) in relapsed or refractory multiple myeloma: recommendations for clinical practice
Annals of Hematology·2025Open Access
Talquetamab alters T cell transcriptome in presence of GPRC5D on MM cells
Blood·2025
Lattice light-sheet microscopy reveals patient specific responses to CD20-directed antibodies in B cell malignancies
Blood·2025
Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and adverse outcome of CAR-T therapy
Blood·2025
Tumor intrinsic mechanisms leading to cevostamab resistance in multiple myeloma
Blood·2025Open Access
An acquired immune-metabolic shift to common chemotherapy confers resistance to immunotherapies in relapsed, high-risk multiple myeloma
Blood·2025Open Access
Modeling of a hyper-inflammatory hematopoietic niche ex vivo reveals a multi-step process driving CAR T- cell associated myeloid leukemia in multiple myeloma
Blood·2025Open Access
NQO1 modulates CD38 surface expression in multiple myeloma
Blood·2025
Single-cell profiling reveals teclistamab-induced reshaping of nasopharyngeal immunity in multiple myeloma
Blood·2025
Increased teclistamab dosing interval improves T-cell diversity and reduces infection risk, while T-cell exhaustion remains minimal irrespective of schedule
Blood·2025Open Access
Impact of bortezomib on T-cell subsets and immune checkpoints under bispecific antibody therapy in multiple myeloma
Blood·2025Open Access
Upregulation of BCMA expression by selinexor
Blood·2025Open Access
page 1 of 10Next →

Frequent Co-authors

K. Martin Kortüm(19), Leo Rasche(19), Hermann Einsele(18), Ralph Wäsch(16), Monika Engelhardt(16), Julia Mersi(13), Gabriele Ihorst(12), Xiang Zhou(10), Umair Munawar(10), Seungbin Han(10), Birgit Knoechel(8), Jens G. Lohr(8), Maximilian Steinhardt(8), Christine Riedhammer(8), Cornelia Vogt(8), Silvia Nerreter(8), Dagmar Wider(7), Praveen Anand(7), Marie Follo(6), Justus Duyster(6)